{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:14:09Z","timestamp":1790118849324,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"ASKLEPIOS \u2013 Advanced Studies towards Knowledge on Lyssavirus Encephalitis Pathogenesis Improving Options for Survival","award":["602825"],"award-info":[{"award-number":["602825"]}]},{"name":"Defra grant","award":["SE0431"],"award-info":[{"award-number":["SE0431"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2017.10.109","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T12:00:14Z","timestamp":1510315214000},"page":"4686-4693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Re-evaluating the effect of Favipiravir treatment on rabies virus infection"],"prefix":"10.1016","volume":"37","author":[{"given":"Ashley C.","family":"Banyard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Selden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Koraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.M.E.","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Fooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.10.109_b0005","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(13)62707-5","article-title":"Current status of rabies and prospects for elimination","volume":"384","author":"Fooks","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.10.109_b0010","unstructured":"WHO. Human and dog rabies prevention and control. Report of the WHO\/Bill & Melinda Gates Foundation Consultation. Annecy, France; 2010."},{"key":"10.1016\/j.vaccine.2017.10.109_b0015","unstructured":"WHO. WHO Expert Consultation on Rabies, Second report. WHO technical report series; no. 982. Geneva, Switzerland: World Health Organization; 2013."},{"key":"10.1016\/j.vaccine.2017.10.109_b0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/QCO.0b013e3282fc705b","article-title":"Emerging aspects of rabies infection: with a special emphasis on children","volume":"21","author":"Warrell","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.109_b0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0035-9203(76)90037-7","article-title":"The clinical picture of rabies in man","volume":"70","author":"Warrell","year":"1976","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.10.109_b0030","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1186\/s13104-014-0955-1","article-title":"Knowledge, attitudes and practices regarding rabies and exposure to bats in two rural communities in Guatemala","volume":"8","author":"Moran","year":"2015","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.vaccine.2017.10.109_b0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40249-015-0061-1","article-title":"On dogs, people, and a rabies epidemic: results from a sociocultural study in Bali, Indonesia","volume":"4","author":"Widyastuti","year":"2015","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.vaccine.2017.10.109_b0040","first-page":"55","article-title":"A pilot study on the usefulness of information and education campaign materials in enhancing the knowledge, attitude and practice on rabies in rural Sri Lanka","volume":"3","author":"Matibag","year":"2009","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.vaccine.2017.10.109_b0045","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1371\/journal.pntd.0000839","article-title":"Rabies, still neglected after 125 years of vaccination","volume":"4","author":"Bourhy","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.10.109_b0050","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(11)70340-1","article-title":"Passive immunity in the prevention of rabies","volume":"12","author":"Both","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.109_b0055","article-title":"Current status and development of vaccines and other biologics for human rabies prevention","volume":"1\u201319","author":"Rupprecht","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.10.109_b0060","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03679","article-title":"Favipiravir elicits antiviral mutagenesis during virus replication in vivo","volume":"3","author":"Arias","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.vaccine.2017.10.109_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002790","article-title":"Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational rift valley fever","volume":"8","author":"Caroline","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.10.109_b0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3851\/IMP1729","article-title":"Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir","volume":"21","author":"Buys","year":"2011","journal-title":"Antiviral Chem Chemother"},{"key":"10.1016\/j.vaccine.2017.10.109_b0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.antiviral.2008.07.009","article-title":"Efficacy of orally-administered T-705 pyrazine analog on lethal West Nile virus infection in rodents","volume":"80","author":"Morrey","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2017.10.109_b0080","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.10.109_b0085","doi-asserted-by":"crossref","unstructured":"Oestereich L, L\u00fcdtke A, Wurr S, Rieger T, Mu\u00f1oz-Fontela C, G\u00fcnther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014;105:17\u201321.","DOI":"10.1016\/j.antiviral.2014.02.014"},{"key":"10.1016\/j.vaccine.2017.10.109_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001342","article-title":"Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever","volume":"5","author":"Mendenhall","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.10.109_b0095","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of Favipiravir (T-705) in rabies postexposure prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.109_b0100","first-page":"1253","article-title":"T-705 as a potential therapeutic agent for rabies","volume":"213","author":"Virojanapirom","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.109_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2851","article-title":"Antiviral therapy for human rabies","volume":"20","author":"Appolinario","year":"2015","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.vaccine.2017.10.109_b0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","article-title":"Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody","volume":"212","author":"Cliquet","year":"1998","journal-title":"J Immunol Methods."},{"key":"10.1016\/j.vaccine.2017.10.109_b0115","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1073\/pnas.93.11.5653","article-title":"Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America","volume":"93","author":"Morimoto","year":"1996","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2017.10.109_b0120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virusres.2012.12.011","article-title":"Pathobiology of rabies virus and the European bat lyssaviruses in experimentally infected mice","volume":"172","author":"Healy","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2017.10.109_b0125","unstructured":"Dean DJ, Abelseth MK. Laboratory techniques in rabies: the fluorescent antibody test. Monograph Series of the World Health Organisation; 1973. pp. 73\u201384."},{"key":"10.1016\/j.vaccine.2017.10.109_b0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jviromet.2011.07.002","article-title":"A universal real-time assay for the detection of Lyssaviruses","volume":"177","author":"Hayman","year":"2011","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2017.10.109_b0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.antiviral.2015.09.015","article-title":"Meeting report: 28th International Conference on Antiviral Research in Rome, Italy","volume":"123","author":"Hodge","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2017.10.109_b0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds; novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2017.10.109_b0145","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1586\/eri.10.50","article-title":"Why does the prognosis remain so poor in human rabies?","volume":"8","author":"Jackson","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.vaccine.2017.10.109_b0150","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.antiviral.2013.01.003","article-title":"Current and future approaches to the therapy of human rabies","volume":"99","author":"Jackson","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2017.10.109_b0155","doi-asserted-by":"crossref","unstructured":"Castel G, Ben-Mechlia M, Jallet C, Tordo N. Rabies therapeutics: development of anti-viral approaches. In: Nagarajan CRT, editor. Current Laboratory Techniques in Rabies Diagnosis, Research and Prevention; 2015.","DOI":"10.1016\/B978-0-12-801919-1.00027-0"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T17:43:50Z","timestamp":1564163030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17315414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":31,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X17315414"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.109","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-evaluating the effect of Favipiravir treatment on rabies virus infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}